

Supplementary Table 1. Antidiabetic treatment at each time point

Treatment patterns	No. (%)	Daily total insulin dose, U
Week -26 (pre-switching)		
OADs	177 (90.30)	-
Insulin regimens	196 (100.00)	37.43±21.80
Basal insulin	105 (53.57)	28.59±16.51
Basal-prandial insulin	20 (10.20)	54.75±29.00
Premix insulin	71 (36.22)	45.62±20.50
GLP-1 RA	7 (3.57)	-
Week 0 (baseline)		
OADs	176 (89.80)	-
Insulin regimens	196 (100.00)	39.15±20.90
IDegAsp	183 (93.37)	39.30±21.15
IDegAsp plus prandial insulin	13 (6.63)	37.08±17.85
GLP-1 RA	1 (0.51)	-
Week 26 (post-switching)		
OADs	176 (89.80)	-
Insulin regimens	196 (100.00)	41.14±22.91
IDegAsp	180 (91.84)	40.91±23.25
IDegAsp plus prandial insulin	16 (8.16)	43.69±19.11
GLP-1 RA	1 (0.51)	-

Values are presented as number (%) or mean±standard deviation.

OAD, oral antidiabetic drug; GLP-1 RA, glucagon-like peptide-1 receptor agonist; IDegAsp, insulin degludec/insulin aspart.